This week, rheumatologists and rheumatology stakeholders from the American College of Rheumatology (ACR) took to Capitol Hill to advocate on pressing issues in rheumatology care, such as the rising costs of treatment and lack of access to care.
This week, rheumatologists and rheumatology stakeholders from the American College of Rheumatology (ACR) took to Capitol Hill to advocate on pressing issues in rheumatology care, such as the rising costs of treatment and lack of access to care.
ACR members urged lawmakers to support legislation that would limit the use of step therapy, grow the rheumatology workforce, create more transparency in drug pricing, and hold pharmacy benefit managers accountable for their part in practices that have increased out-of-pocket costs for patients.
Additionally, ACR encouraged leaders to support the following legislation that would address the increasing costs and barriers in access, among others:
Finally, ACR urged members of the House and Senate Appropriations Subcommittees on Defense to create a line item in the Congressionally Designated Medical Research Program (CDMRP) for arthritis at the Department of Defense using an existing $20 million in funds. The creation of this program would address the needs of active duty military personnel and veterans who have osteoarthritis and other rheumatic diseases.
“We are at a critical juncture in rheumatology care…the rheumatology workforce is not growing fast enough to keep up with demand and too many of our patients struggle to access and afford the breakthrough therapies they need to manage their pain and avoid long-term disability,” said David Daikh, MD, PhD, president of ACR, in a prepared statement.
The American College of Rheumatology’s Advocacy Leadership Conference was held on May 16 to May 17, 2018 in Washington, D.C.
Eye on Pharma: BI Cyltezo Partnership; Europe Ustekinumab Launch; Mexico Biosimilar Approval
July 24th 2024Boehringer Ingelheim (BI) partners with GoodRx to offer its unbranded adalimumab biosimilar to patients at an exclusive low price; a new ustekinumab biosimilar launches in Europe; and Mexican officials approve a bevacizumab biosimilar.
Biosimilars in America: Overcoming Barriers and Maximizing Impact
July 21st 2024Join us as we explore the complexities of the US biosimilars market, discussing legislative influences, payer and provider adoption factors, and strategies to overcome industry challenges with expert insights from Kyle Noonan, PharmD, MS, value & access strategy manager at Cencora.
Breaking Barriers in Osteoporosis Care: New Denosumab Biosimilars Wyost, Jubbonti Approved
June 16th 2024In this episode, The Center for Biosimilars® delves into the FDA approval of the first denosumab biosimilars, Wyost and Jubbonti (denosumab-bbdz), and discuss their potential to revolutionize osteoporosis treatment with expert insights from 2 rheumatologists.
Hesitancy in MENA Nations to Adopt WHO Biosimilar Guidelines Hinders Market Development
July 17th 2024The World Health Organization’s (WHO) new guidelines for biosimilar approvals aim to save time and money for manufacturers in the Middle East and North Africa (MENA), but hesitancy among nations to adopt the guidelines is stifling market development of biosimilars.